Novo Nordisk's Ozempic And Wegovy Helps Lose Weight, Not One's Mind: US Study Find No Increased Suicidal Thoughts Risk
Portfolio Pulse from Vandana Singh
A U.S. study found that Novo Nordisk's drugs Ozempic and Wegovy do not increase the risk of suicidal thoughts. Contrary to prior concerns, the study showed a lower incidence of such thoughts among users compared to other treatments. The study, funded by the U.S. National Institutes of Health and published in 'Nature,' analyzed data from over 1.8 million patients. Semaglutide, the active ingredient in both drugs, was linked to a significantly lower risk of suicidal ideations. Novo Nordisk's stock (NVO) was down 0.60% at $106.99 on the last check Friday.
January 05, 2024 | 3:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novo Nordisk's drugs Ozempic and Wegovy are found to be safe regarding the risk of suicidal thoughts, potentially reinforcing the drugs' market position and alleviating concerns from patients and healthcare providers.
The positive outcome of the study is likely to increase trust in Ozempic and Wegovy, which could lead to sustained or increased usage of these drugs. This news may counteract the slight stock price decline seen on Friday, as it addresses prior safety concerns that could have affected the drugs' perception negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100